No Data
No Data
Reported Sunday, Bluebird Bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024
Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Trending Stocks Today | PainReform Surges 67.16% Post-Market
Express News | Bluebird bio Announces 1-for-20 Reverse Stock Split
Bluebird Bio Announces 1-for-20 Reverse Stock Split